Qidwai Waris
Department of Family Medicine, Aga Khan University, Karachi, Pakistan.
J Pak Med Assoc. 2024 Nov;74(11 (Supple-12)):S24-S27. doi: 10.47391/JPMA.AKU-EPP-06.
This manuscript examines the ethics of the relationship between the pharmaceutical industry and practising physicians. The pharmaceutical industry is alleged to provide incentives to physicians and who in return are expected to prescribe their manufactured medications. Such practices are often considered unethical and against the rules and regulations of the regulatory bodies. The core issue facing physicians and pharmaceutical industry relationships is lack of regulation and accountability. Public education and awareness are lacking, and they are unable to question prescription practices of practicing physicians. Patient advocacy groups do not exist to safeguard the patient's rights. There is a need to strengthen regulatory control to ensure the physician community and pharmaceutical industry relationship remains ethical. Both the physician community and pharmaceutical industry are important stakeholders in healthcare delivery and the ethical relationship between them will benefit health care services. Further discussion and debate on this important yet extremely sensitive issue is strongly recommended.
本手稿探讨了制药行业与执业医师之间关系的伦理问题。据称，制药行业会向医师提供激励措施，而作为回报，医师则应开具其生产的药物。此类做法通常被视为不道德且违反监管机构的规章制度。医师与制药行业关系面临的核心问题是缺乏监管和问责制。公众教育和意识不足，他们无法质疑执业医师的处方行为。不存在患者权益倡导组织来保障患者的权利。有必要加强监管控制，以确保医师群体与制药行业的关系保持道德。医师群体和制药行业都是医疗服务提供中的重要利益相关者，它们之间的道德关系将有利于医疗服务。强烈建议就这一重要但极其敏感的问题展开进一步的讨论和辩论。
